Clinical trials: Remission
Dermatitis, Atopic
Curing Atopic Dermatits in Children With a Commerical Medical Device and Maintaining Healthy Skin by Using a New Cosmetic Product
1. Curing mild atopic dermatis in children with a commerical medical device (Bepanthen Itch Relief Cream). 2. Maintaining healthy skin by using a new cosmetic Bepanthen product or a commercially available cosmetic product
- Trial name
- NCT02615561
- Testing
- Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543), New cosmetic Bepanthen product: Pumpkin (BAY207543), Stelatopia (cosmetic comparator)
- Where
- 14 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Bayer
Leukemia
Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate
RATIONALE: Drugs used in chemotherapy, such as everolimus, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00093639
- Testing
- everolimus, imatinib mesylate
- Where
- United States
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease
The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.
- Trial name
- NCT00445939
- Testing
- adalimumab
- Where
- 18 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Abbott
Ulcerative Colitis
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC).
- Trial name
- NCT06095128
- Testing
- Vedolizumab, Tofacitinib
- Where
- 45 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Takeda
Crohn's Disease
Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease
The current multicentre phase III study is proposed to confirm in an add-on therapy design compared to a placebo-control group, the efficacy of adipose-derived stem cells (eASCs) from healthy donors for the treatment of complex…
- Trial name
- ADMIRE-CD (NCT01541579)
- Testing
- Cx601, Saline solution
- Where
- 52 sites in Austria, Belgium and 6 more
- Volunteers
- 278 people
- Sponsor
- Tigenix S.A.U.
Ovarian Cancer
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
The study was a Phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial of vismodegib (GDC-0449) in patients with ovarian cancer in a second or third complete remission.
- Trial name
- NCT00739661
- Testing
- Vismodegib 150 mg
- Volunteers
- 104 people
- Sponsor
- Genentech, Inc.
Diabetes, Diabetes Mellitus, Type 2
Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart
This trial is conducted in Asia. The aim of this trial is evaluate the remission rate in newly diagnosed subjects with type 2 diabetes after short-term intensive treatment with insulin aspart and insulin NPH.
- Trial name
- NCT00494988
- Testing
- insulin aspart, insulin NPH
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Digital, Blended Lifestyle Intervention for Type 2 Diabetes Remission
410 Dutch type 2 diabetes patients will be randomized using a 5:1 ratio to intervention group versus control, to a lifestyle intervention program given via a mobile application and digital platform.
- Trial name
- IBIDEM (NCT05346614)
- Testing
- Lifestyle intervention
- Where
- 4 sites in Netherlands
- Volunteers
- 410 people
- Sponsor
- Ancora Health B.V.
Crohn Disease
Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease
The primary objective of this extension study was to obtain long-term safety data for BIRB 796 BS in patients with moderate to severe Crohn's disease after 26 weeks of treatment.
- Trial name
- NCT02209792
- Testing
- BIBR 796 BS, 5 mg, BIBR 796 BS, 20 mg
- Volunteers
- 284 people
- Sponsor
- Boehringer Ingelheim
Ulcerative Colitis
CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission
This dose comparison study, taking place at over 200 sites worldwide, will compare the dosing, safety and efficacy of an investigational medicine OPC-6535 to the dosing, safety and efficacy of Asacol ® in the maintenance of…
- Trial name
- NCT00092508
- Testing
- OPC-6535, Asacol®
- Where
- 26 sites in United States
- Volunteers
- 1,725 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Acute Myeloid Leukemia
DC Vaccination for Post-remission Therapy in AML
This is a multi-centre, open label, prospective, non-randomized phase I/II trial in 20 patients including a safety-run in phase I part comprising 6 patients.
- Trial name
- NCT02405338
- Testing
- WT1/PRAME vaccination
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Medigene AG
Colitis, Ulcerative
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis.
- Trial name
- EFFECT-UC (NCT06294925)
- Testing
- Etrasimod
- Where
- 41 sites in Canada, Germany and 1 more
- Volunteers
- 360 people
- Sponsor
- Pfizer
Crohn's Disease
Bologna IBD Markers
Individuate possible predictive factors of anti-TNFalfa-induced deep remission in Crohn's disease.
- Trial name
- NCT02580864
- Where
- Italy
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Colitis, Ulcerative, Recurrence
Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)
This study intends to study the efficacy and tolerability of once daily 3.0 g mesalazine granules vs. once daily 1.5 g mesalazine granules vs.
- Trial name
- NCT00746447
- Testing
- mesalamine granules
- Where
- Germany
- Volunteers
- 648 people
- Sponsor
- Dr. Falk Pharma GmbH
Depression in Remission
A Study of SDI-118 in Participants in Remission From Depression
This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on male and female study participants reporting…
- Trial name
- NCT05212116
- Testing
- SDI-118
- Where
- 3 sites in United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Syndesi Therapeutics
Acute Myeloid Leukemia
CNDO-109-AANK for AML in First Complete Remission (CR1)
This is a multi-center, open-label, non-controlled, non-randomized dose-escalating Phase 1 clinical study designed to examine the safety of infusing escalating doses of CNDO-109-Activated Allogeneic Natural Killer Cells-(from a…
- Trial name
- NCT01520558
- Testing
- CNDO-109-AANK Cells
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Coronado Biosciences, Inc.
Crohn's Disease
Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease
This is a multi-centre, open-label extension study in subjects who showed clinical response to induction therapy in the treatment of subjects with active Crohn's disease in the double-blind main study C87037 (NCT00291668).
- Trial name
- NCT00329550
- Testing
- Certolizumab pegol (CZP)
- Where
- 23 sites in Japan
- Volunteers
- 40 people
- Sponsor
- UCB Japan Co. Ltd.
Ulcerative Colitis in Remission
Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase
To demonstrate that import Mesalazine (ASACOL®) is non-inferior to the reference drug, marketed Mesalazine, regarding the primary endpoint (rate of non-emergence of bloody stool), in patients with Ulcerative Colitis in remission…
- Trial name
- NCT01257399
- Testing
- Asacol®, Mesalazine
- Where
- China
- Volunteers
- 251 people
- Sponsor
- Tillotts Pharma AG
Ulcerative Colitis
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.
- Trial name
- NCT03281304
- Testing
- CP-690,500 5 mg, CP-690,550 10 mg
- Where
- 80 sites in United States, Belgium and 18 more
- Volunteers
- 140 people
- Sponsor
- Pfizer
Metabolic Syndrome
Trial to Evaluate the Effect of Plantago Ovata Husk in the Remission of Metabolic Syndrome in Children and Adolescents
The metabolic syndrome represents a constellation of risk factors associated to the abdominal obesity that includes insulin resistance, lipids alterations, high blood pressure etc.
- Trial name
- NCT00748787
- Testing
- Ispaghula husk
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- Rottapharm Spain